Literature DB >> 10078636

Radiosurgery for brain metastases: is whole brain radiotherapy necessary?

P K Sneed1, K R Lamborn, J M Forstner, M W McDermott, S Chang, E Park, P H Gutin, T L Phillips, W M Wara, D A Larson.   

Abstract

PURPOSE: Because whole brain radiotherapy (WBRT) may cause dementia in long-term survivors, selected patients with brain metastases may benefit from initial treatment with radiosurgery (RS) alone reserving WBRT for salvage as needed. We reviewed results of RS +/- WBRT in patients with newly diagnosed brain metastasis to provide background for a prospective trial. METHODS AND MATERIALS: Patients with single or multiple brain metastases managed initially with RS alone vs. RS + WBRT (62 vs. 43 patients) from 1991 through February 1997 were retrospectively reviewed. The use of upfront WBRT depended on physician preference and referral patterns. Survival, freedom from progression (FFP) endpoints, and brain control allowing for successful salvage therapy were measured from the date of diagnosis of brain metastases. Actuarial curves were estimated using the Kaplan-Meier method. Analyses to adjust for known prognostic factors were performed using the Cox proportional hazards model (CPHM) stratified by primary site.
RESULTS: Survival and local FFP were the same for RS alone vs. RS + WBRT (median survival 11.3 vs. 11.1 months and 1-year local FFP by patient 71% vs. 79%, respectively). Brain FFP (scoring new metastases and/or local failure) was significantly worse for RS alone vs. RS + WBRT (28% vs. 69% at 1 year; CPHM adjustedp = 0.03 and hazard ratio = 0.476). However, brain control allowing for successful salvage of a first failure was not significantly different for RS alone vs. RS + WBRT (62% vs. 73% at 1 year; CPHM adjusted p = 0.56).
CONCLUSIONS: The omission of WBRT in the initial management of patients treated with RS for up to 4 brain metastases does not appear to compromise survival or intracranial control allowing for salvage therapy as indicated. A randomized trial of RS vs. RS + WBRT is needed to assess survival, quality of life, and cost in good-prognosis patients with newly diagnosed brain metastases.

Entities:  

Mesh:

Year:  1999        PMID: 10078636     DOI: 10.1016/s0360-3016(98)00447-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  64 in total

Review 1.  Management of brain metastasis: past lessons, modern management, and future considerations.

Authors:  Eugene Koay; Erik P Sulman
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

2.  The role of radiosurgery in patients with brain metastasis from small cell lung carcinoma.

Authors:  Kwang Wook Jo; Doo Sik Kong; Do Hoon Lim; Yong Chan Ahn; Do-Hyun Nam; Jung-Il Lee
Journal:  J Korean Neurosurg Soc       Date:  2011-08-31

Review 3.  Radiotherapy and chemotherapy of brain metastases.

Authors:  R Soffietti; A Costanza; E Laguzzi; M Nobile; R Rudà
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

4.  Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study.

Authors:  Martin Kocher; Riccardo Soffietti; Ufuk Abacioglu; Salvador Villà; Francois Fauchon; Brigitta G Baumert; Laura Fariselli; Tzahala Tzuk-Shina; Rolf-Dieter Kortmann; Christian Carrie; Mohamed Ben Hassel; Mauri Kouri; Egils Valeinis; Dirk van den Berge; Sandra Collette; Laurence Collette; Rolf-Peter Mueller
Journal:  J Clin Oncol       Date:  2010-11-01       Impact factor: 44.544

5.  Research on climate change and health: looking ahead.

Authors:  Sari Kovats
Journal:  Int J Public Health       Date:  2010-04       Impact factor: 3.380

6.  Hypofractionated stereotactic radiotherapy in combination with whole brain radiotherapy for brain metastases.

Authors:  Cesare Giubilei; Gianluca Ingrosso; Marco D'Andrea; Michaela Benassi; Riccardo Santoni
Journal:  J Neurooncol       Date:  2008-09-19       Impact factor: 4.130

7.  Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study.

Authors:  Tarek Mekhail; Michael Sombeck; Robert Sollaccio
Journal:  Curr Oncol Rep       Date:  2011-08       Impact factor: 5.075

Review 8.  Current approaches to the treatment of metastatic brain tumours.

Authors:  Taofeek K Owonikoko; Jack Arbiser; Amelia Zelnak; Hui-Kuo G Shu; Hyunsuk Shim; Adam M Robin; Steven N Kalkanis; Timothy G Whitsett; Bodour Salhia; Nhan L Tran; Timothy Ryken; Michael K Moore; Kathleen M Egan; Jeffrey J Olson
Journal:  Nat Rev Clin Oncol       Date:  2014-02-25       Impact factor: 66.675

9.  Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.

Authors:  Brunilde Gril; Diane Palmieri; Julie L Bronder; Jeanne M Herring; Eleazar Vega-Valle; Lionel Feigenbaum; David J Liewehr; Seth M Steinberg; Maria J Merino; Stephen D Rubin; Patricia S Steeg
Journal:  J Natl Cancer Inst       Date:  2008-07-29       Impact factor: 13.506

Review 10.  The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Mark E Linskey; David W Andrews; Anthony L Asher; Stuart H Burri; Douglas Kondziolka; Paula D Robinson; Mario Ammirati; Charles S Cobbs; Laurie E Gaspar; Jay S Loeffler; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Roy A Patchell; Timothy C Ryken; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2009-12-04       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.